Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

0.8419 -0.0116 (-1.36%)
Streaming Delayed Price Updated: 9:31 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Oncolytics Biotech Inc. - Common Shares

< Previous 1 2 3 Next >
News headline image
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug ↗
The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer. 
Via Stocktwits
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview: Oncolytics Biotech ↗
 
Via Benzinga
News headline image
Recap: Oncolytics Biotech Q4 Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 8, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Oncolytics Biotech's Earnings ↗
 
Via Benzinga
News headline image
A Preview Of Oncolytics Biotech's Earnings ↗
 
Via Benzinga
News headline image
Oncolytics Biotech's Earnings Outlook ↗
 
Via Benzinga
News headline image
Oncolytics Biotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Oncolytics Biotech ↗
 
Via Benzinga
News headline image
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
A Look at Oncolytics Biotech's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Earnings Scheduled For March 7, 2025 ↗
 
Via Benzinga
News headline image
Expert Ratings for Oncolytics Biotech ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer
Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer 
Via News Direct
News headline image
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024 ↗
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023 ↗
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
3 Under-$20 Stocks to Buy for Explosive Returns ↗
Are you looking to invest in stocks with massive potential? Here are three under $20 stocks to buy for explosive returns. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2023 ↗
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
News headline image
Earnings Scheduled For August 14, 2023 ↗
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
News headline image
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
News headline image
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.